Ninety One UK Ltd raised its holdings in shares of Agilent Technologies Inc (NYSE:A) by 3.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 273,282 shares of the medical research company’s stock after buying an additional 9,357 shares during the period. Ninety One UK Ltd’s holdings in Agilent Technologies were worth $24,150,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Blue Square Asset Management LLC bought a new position in shares of Agilent Technologies during the 2nd quarter worth approximately $25,000. Sterling Investment Advisors Ltd. bought a new position in shares of Agilent Technologies in the second quarter valued at $35,000. Patriot Financial Group Insurance Agency LLC grew its stake in shares of Agilent Technologies by 1,570.8% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 401 shares of the medical research company’s stock valued at $35,000 after buying an additional 377 shares in the last quarter. Ameritas Investment Company LLC grew its stake in shares of Agilent Technologies by 169.1% in the first quarter. Ameritas Investment Company LLC now owns 444 shares of the medical research company’s stock valued at $31,000 after buying an additional 279 shares in the last quarter. Finally, TCTC Holdings LLC bought a new position in shares of Agilent Technologies in the second quarter valued at $41,000.
In related news, SVP Dominique Grau sold 6,485 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $100.00, for a total value of $648,500.00. Following the completion of the transaction, the senior vice president now owns 104,154 shares of the company’s stock, valued at $10,415,400. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 72,716 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $95.76, for a total value of $6,963,284.16. Following the completion of the transaction, the chief executive officer now directly owns 575,215 shares of the company’s stock, valued at approximately $55,082,588.40. The disclosure for this sale can be found here. Insiders have sold 85,392 shares of company stock valued at $8,219,555 in the last three months.
Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, August 18th. The medical research company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.12. Agilent Technologies had a return on equity of 20.57% and a net margin of 13.23%. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter last year, the firm earned $0.76 earnings per share. The company’s revenue was down .8% on a year-over-year basis. As a group, analysts predict that Agilent Technologies Inc will post 3.22 earnings per share for the current year.
Several research firms recently weighed in on A. UBS Group raised their target price on shares of Agilent Technologies from $84.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, May 22nd. Cowen raised their target price on shares of Agilent Technologies from $80.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, May 22nd. Zacks Investment Research cut shares of Agilent Technologies from a “buy” rating to a “hold” rating and set a $89.00 target price for the company. in a research note on Friday, June 12th. Credit Suisse Group raised their price target on Agilent Technologies from $53.00 to $54.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Finally, Bank of America raised their price target on Agilent Technologies from $99.00 to $103.00 and gave the company a “neutral” rating in a report on Wednesday, August 19th. Fourteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $87.05.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Read More: Bar Chart
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.